Arlington-based Abexxa Biologics Inc. has been acquired by a German pharmaceutical company. Boehringer Ingelheim plans to use Abexxa’s tech in targeting cancer-specific proteins located inside the cell to boost its tumor-antigen discovery and ways of targeting intracellular antigens. It could lead to new cancer immunotherapies that are effective in a broader range of patients. In 2016, Boehringer’s investment arm awarded Abexxa its initial investment funding. Abexxa then won its Ingelheim’s Innovation Prize later that year.